A5024105914- Cancer Immunotherapy and Biomarkers
- Cardiac tumors and thrombi
- Multiple and Secondary Primary Cancers
- Cancer Diagnosis and Treatment
- Melanoma and MAPK Pathways
- Cutaneous Melanoma Detection and Management
- Ferroptosis and cancer prognosis
- Renal cell carcinoma treatment
- Ubiquitin and proteasome pathways
- Immunotherapy and Immune Responses
- Bone Tumor Diagnosis and Treatments
- Sarcoma Diagnosis and Treatment
- Advanced Breast Cancer Therapies
- Peptidase Inhibition and Analysis
- Chemotherapy-related skin toxicity
- Protein Degradation and Inhibitors
- Cardiac Structural Anomalies and Repair
- Cutaneous lymphoproliferative disorders research
- Lymphoma Diagnosis and Treatment
- Cancer, Lipids, and Metabolism
- Cancer-related Molecular Pathways
- Bladder and Urothelial Cancer Treatments
- CAR-T cell therapy research
- Drug-Induced Adverse Reactions
- Vascular Tumors and Angiosarcomas
University of Miami
2021-2025
Sylvester Comprehensive Cancer Center
2023-2024
Jackson Memorial Hospital
2022-2023
Data on the safety profiles and clinical outcomes of patients with solid tumors cardiac metastasis treated immune checkpoint inhibitors (ICIs) are limited. This is an international multicenter retrospective study cancer at baseline. Patients who had received ≥1 dose ICI were included. Treatment-related adverse events (trAEs) graded per Common Terminology Criteria for Adverse Event V.5.0. Objective response rates (ORR) evaluated by Response Evaluation in Solid Tumors V.1.1 when available....
Abstract Background Combination immune checkpoint blockade targeting programmed cell death protein 1 (PD-1) and cytotoxic T-lymphocyte associated 4 (CTLA-4) leads to high response rates improved survival in patients with advanced cutaneous melanoma (CM). Less is known about the efficacy of this combination acral lentiginous (ALM). Objectives To determine PD-1 CTLA-4 a diverse, real-world population ALM. Methods This multi-institutional retrospective study analysed histologically confirmed...
Abstract Renal cell carcinoma (RCC) is amongst the ten most prevalent malignancies in United States, with 76,000 new cases each year and almost 14,000 deaths. Over past half-century, RCC has more than doubled incidence. seems to have a greater incidence among Hispanics nearly three-fold increase. The epidemiology of been studied. However, there gap knowledge on disparities within minority populations. We aimed analyze epidemiologic patterns our community, where alone make up 70% population....
e16555 Background: Annually, there are over 400,000 new renal cell carcinoma (RCC) cases and more than 170,000 deaths worldwide. In the US, 80,000 of RCC diagnosed each year almost 14,000 deaths. Over past half-century, has doubled in incidence. seems to have a greater incidence among Hispanics, with nearly three-fold increase. The epidemiology Caucasian population been previously studied. However, is knowledge gap on disparities minority populations. Studying Hispanics integral our...
e16554 Background: Annually, there are over 400,000 new renal cell carcinoma (RCC) cases and more than 170,000 deaths worldwide. RCC is one of the top ten prevalent malignancies in United States, with 76,000 each year almost 14,000 deaths. Over past half-century, has doubled incidence. Studies demonstrate histologic differences outcome disparities among Hispanic Latino patients diagnosed RCC. Research to date describes earlier advanced diseases at diagnosis, higher rates obesity...
A 66-year-old African American man with metastatic prostate cancer presented to clinic a pruritic rash in his chest of 1 week duration. He was started on androgen-antagonist therapy enzalutamide month ago. Medical history significant for chronic obstructive pulmonary disease,
561 Background: The RAS pathway regulates tumorigenesis and cell proliferation. HRAS is a family member that activates via farnesylation. Indirectly targeting mutant with tipifarnib, farnesyltransferase inhibitor (FTI), recently demonstrated efficacy in head neck tumors. We aimed to investigate the molecular characteristics clinical outcomes of mutations (HRASmut) for any potential role as prognostic therapeutic biomarker breast cancer (BC). Methods: A total 14,013 BC tissue samples had...
e19524 Background: T-cell lymphomas are a heterogeneous group of lymphomas, including the cutaneous T cell lymphoma (CTCL) and peripheral (PTCL). Regarding PTCL, it’s approximately 23 different diseases with not otherwise specified (PTCL NOS), angioimmunoblastic (AITL), anaplastic large (ALCL) being most frequent subtypes. In contrast B PTCL have worse prognosis. We aim in our study to quantify prognosis each subtypes PTCL. Methods: analyzed patients either NOS, AITL, or ALCL treated at...